Retatrutide (GLP-1/GIP/Glucagon Triple Agonist): What Researchers Need to Know

Retatrutide (GLP-1/GIP/Glucagon Triple Agonist)
What Researchers Need to Know

A review of mechanism, Phase 2 clinical data, and laboratory research considerations for RETAKLIK

⚗️ For laboratory and research use only. All materials supplied by Eurovits are strictly for scientific research purposes and are not intended for human or veterinary use.

Introduction

Among the most closely watched compounds in metabolic research today, retatrutide — a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — represents a significant step forward from earlier dual-agonist peptides. At Eurovits, we supply RETAKLIK (Retatrutide) as a high-purity research material for qualified laboratories investigating metabolic pathways, energy homeostasis, and receptor pharmacology.

Mechanism of Action

Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist), retatrutide engages three distinct receptor pathways:

  • GLP-1 receptor — promotes insulin secretion, reduces glucagon, slows gastric emptying
  • GIP receptor — enhances insulin response and may play a role in adipose tissue regulation
  • Glucagon receptor — increases energy expenditure and hepatic glucose output

Phase 2 Clinical Trial Data — NEJM 2023 (Jastreboff et al.)

The landmark Phase 2 randomised controlled trial published in the New England Journal of Medicine (June 2023) remains the most comprehensive published dataset on retatrutide to date. Key findings over 48 weeks:

  • Mean body weight reduction of up to 24.2% in the highest dose group (12mg), vs. 2.1% placebo
  • All active dose groups (1mg, 4mg, 8mg, 12mg) showed statistically significant weight reduction
  • The 8mg group achieved 22.8%; the 4mg group 17.5%
  • Weight loss was still progressing at week 48 — plateau not yet reached

Metabolic Markers Observed

  • Reductions in fasting insulin and HOMA-IR (insulin resistance index)
  • Improvements in triglycerides, LDL cholesterol, and blood pressure
  • HbA1c reductions across all groups, including participants without type 2 diabetes at baseline

Comparative Context

Compound Receptor Targets Peak Weight Reduction
Semaglutide 2.4mg GLP-1 ~15% (STEP 1)
Tirzepatide 15mg GLP-1 / GIP ~22.5% (SURMOUNT-1)
Retatrutide 12mg GLP-1 / GIP / Glucagon ~24.2% (Phase 2, 48 wks)

Laboratory Research Considerations

  • Storage: Keep lyophilised material sealed and refrigerated; reconstitute with sterile bacteriostatic water
  • Stability: Store reconstituted material at 2–8°C; avoid repeated freeze-thaw cycles
  • Purity: All Eurovits materials are independently lab-tested — COAs available on request
  • Handling: Follow standard peptide handling protocols
⚠️ Research note: The Phase 2 trial was not powered for cardiovascular outcomes and Phase 3 data is still emerging. All findings relate to clinical trial populations only.
All materials supplied by Eurovits are strictly for laboratory and research purposes only and are not intended for human or veterinary use.
© Eurovits — High-Purity Research Materials